At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed May 15, 2026 at 11:45 ET
ProKidney reported Q1 2026 EPS of -$0.14, essentially in line with the -$0.14 consensus (a 1.8% miss), with negligible revenue of $226K. The key catalyst is the on-track enrollment completion for the Phase 3 PROACT 1 accelerated approval analysis in mid-2026, with pivotal topline eGFR slope results expected in Q2 2027. Cash burn continues, with $224.9M in cash supporting operations into mid-2027, but no fundamental financial improvement was reported.
- Q1 2026 EPS of -$0.14 vs consensus -$0.14 (in line, 1.8% miss)
- Revenue of $226K vs consensus $100K (beat, but immaterial for a clinical-stage biotech)
- Cash, cash equivalents and marketable securities: $224.9M as of March 31, 2026, down from $270.0M at year-end 2025
- Net loss before noncontrolling interest: $42.6M in Q1 2026 vs $38.0M in Q1 2025
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access